Journal article · 2026 · Open access
A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial
Nature Medicine, 32(11), 4221–4233 · Published 3 November 2026 · DOI 10.1038/s41591-026-04686-y
In brief
“A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial” is a 2026 journal article by Doris M. Ponce and 31 co-authors, published in Nature Medicine. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Nature Medicine.
- Citations
- 0
- References
- 78
- Authors
- 32
Abstract
Gastrointestinal (GI) microbiome disruption and impaired GI barrier integrity increase the risk of bloodstream infection (BSI) following allogeneic hematopoietic cell transplant. Here we report results from a two-cohort (open-label, n = 15; randomized, placebo-controlled, n = 45) phase 1b study of SER-155, an investigational, cultivated, multi-strain, oral live biotherapeutic designed to address GI microbiome disruption GI epithelial barrier integrity in allogeneic hematopoietic cell transplant recipients. In cohort 2, 34 of 45 participants received either SER-155 treatment (n = 20, SER-155 following microbiome conditioning with oral vancomycin), or placebo (n = 14), and subsequently received transplant. For the primary safety endpoint, SER-155 was well tolerated, with a safety profile comparable to placebo, no treatment-related serious adverse events and no infections with SER-155 species; the most common adverse events were diarrhea and nausea. Four participants in cohort 1 and four participants in cohort 2 (two participants in the SER-155 arm and two in the placebo arm) died during the study; none was attributable to SER-155. For the primary pharmacokinetic endpoint, engraftment was detected for 16 of 16 SER-155 strains, with a median of 11.5 strains detected after the first treatment course. The key secondary efficacy endpoint revealed a significantly lower incidence of BSI with SER-155 versus placebo (10.0% versus 43%; OR 0.15; 95% CI 0.01–1.13; P = 0.0423; 77% relative risk reduction). Other secondary efficacy endpoints (GI infection, acute graft-versus-host disease ≥grade 2, febrile neutropenia and a composite endpoint of BSI, GI infection or acute graft-versus-host disease) were not statistically significant. The secondary pharmacodynamic endpoint of GI domination by Enterococcus and Enterobacteriaceae spp. was not achieved. ClinicalTrials.gov identifier: NCT04995653 . In a phase 1b study that included an open-label and randomized-controlled cohorts of allogeneic hematopoietic cell transplantation recipients, treatment with the investigational, cultivated, multi-strain bacterial oral live biotherapeutic product, SER-155, was found to have a similar safety profile to placebo and resulted in fewer bloodstream infections, indicating further clinical investigation of this therapeutic is warranted.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Ponce, D. M., DeFilipp, Z. M., Ford, C. B., Tejura, B., Lombardo, M., Lichter, D. I., Chafee, M. E., Kosuri, S., Khera, N., Murthy, H. S., Sandhu, K., Fredricks, D. N., Andermann, T. M., Nath, R. P., Brady, K., Hasson, B. R., Walsh, E. K., Hicks, N. D., Peled, J. U., . . . Sykes, S. (2026). A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial. Nature Medicine, 32(11), 4221–4233. https://doi.org/10.1038/s41591-026-04686-y
MLA 9
Ponce, Doris M., et al. “A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial.” Nature Medicine, vol. 32, no. 11, 2026, pp. 4221–4233. https://doi.org/10.1038/s41591-026-04686-y.
Chicago
Ponce, Doris M., Zachariah Michael DeFilipp, Christopher B. Ford, Bina Tejura, Mary‐Jane Lombardo, David I. Lichter, Meghan E. Chafee, et al. 2026. “A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial.” Nature Medicine 32 (11): 4221–4233. https://doi.org/10.1038/s41591-026-04686-y.
Harvard
Ponce, D. M. et al. (2026) ‘A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial’, Nature Medicine, 32(11), pp. 4221–4233. doi:10.1038/s41591-026-04686-y.
IEEE
D. M. Ponce et al., “A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial,” Nature Medicine, vol. 32, no. 11, pp. 4221–4233, 2026, doi: 10.1038/s41591-026-04686-y.
BibTeX
@article{ponce2026live,
title = {{A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial}},
author = {Ponce, Doris M. and DeFilipp, Zachariah Michael and Ford, Christopher B. and Tejura, Bina and Lombardo, Mary‐Jane and Lichter, David I. and Chafee, Meghan E. and Kosuri, Satyajit and Khera, Nandita and Murthy, Hemant S. and Sandhu, Karamjeet and Fredricks, David N. and Andermann, Tessa M. and Nath, Rajneesh P. and Brady, Kelly and Hasson, Brooke R. and Walsh, Emily K. and Hicks, Nathan D. and Peled, Jonathan U. and Von Moltke, Lisa L. and Henn, Matthew R. and van den Brink, Marcel R.M. and Walling, Dennis M. and the SER-155-001 Study Team and Hogan, William J. and Farhadfar, Nosha and Tsai, Steven C. and Al‐Mansour, Zeina and Patel, Chirag H. and Pandian, Swarna and others},
journal = {Nature Medicine},
year = {2026},
volume = {32},
number = {11},
pages = {4221--4233},
doi = {10.1038/s41591-026-04686-y},
url = {https://doi.org/10.1038/s41591-026-04686-y}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- therapeutics
- allogeneic hematopoietic stem cell transplantation
- bloodstream infection
- gastrointestinal microbiome
- vancomycin
- engraftment
- acute graft-versus-host disease
- febrile neutropenia
Work with this paper
Most-cited papers in Agricultural and Biological Sciences
- A Revised Medium for Rapid Growth and Bio Assays with Tobacco Tissue CulturesToshio Murashige, Folke Karl Skoog · Physiologia Plantarum · 1962 · 68,073 citations
- AMPLIFICATION AND DIRECT SEQUENCING OF FUNGAL RIBOSOMAL RNA GENES FOR PHYLOGENETICST. J. White, Thomas D. Bruns, Steven S. Lee and 1 more · Elsevier eBooks · 1990 · 37,197 citations
- Methods for Dietary Fiber, Neutral Detergent Fiber, and Nonstarch Polysaccharides in Relation to Animal NutritionPeter J. Van Soest, James B. Robertson, BERTHA A. LEWIS · Journal of Dairy Science · 1991 · 29,489 citations
- AN EXAMINATION OF THE DEGTJAREFF METHOD FOR DETERMINING SOIL ORGANIC MATTER, AND A PROPOSED MODIFICATION OF THE CHROMIC ACID TITRATION METHODAllan Walkley, Ian Armstrong Black · Soil Science · 1934 · 22,994 citations
- Floral dip: a simplified method for Agrobacterium ‐mediated transformation of Arabidopsis thalianaSteven John Clough, Andrew F. Bent · The Plant Journal · 1998 · 22,047 citations
All highly cited Agricultural and Biological Sciences papers
Questions about this paper
How do I cite this paper in APA style?
Ponce, D. M., DeFilipp, Z. M., Ford, C. B., Tejura, B., Lombardo, M., Lichter, D. I., Chafee, M. E., Kosuri, S., Khera, N., Murthy, H. S., Sandhu, K., Fredricks, D. N., Andermann, T. M., Nath, R. P., Brady, K., Hasson, B. R., Walsh, E. K., Hicks, N. D., Peled, J. U., . . . Sykes, S. (2026). A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial. Nature Medicine, 32(11), 4221–4233. https://doi.org/10.1038/s41591-026-04686-y
How many times has this paper been cited?
0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Nature Medicine: sign in and open the PDF from this page.
Who wrote this paper?
Doris M. Ponce, Zachariah Michael DeFilipp, Christopher B. Ford, Bina Tejura, Mary‐Jane Lombardo, David I. Lichter, Meghan E. Chafee, Satyajit Kosuri, Nandita Khera, Hemant S. Murthy, Karamjeet Sandhu, David N. Fredricks and 20 more.
What is the DOI of this paper?
10.1038/s41591-026-04686-y, permanently at https://doi.org/10.1038/s41591-026-04686-y. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.